Clonal evolutionary analysis during HER2 blockade in HER2-positive inflammatory breast cancer: a phase II open-label clinical trial of afatinib +/- vinorelbine
More about Open Access at the CrickAuthors list
Gerald Goh Ramona Schmid Kelly Guiver Wichit Arpornwirat Imjai Chitapanarux Vinod Ganju Seock-Ah Im Sung-Bae Kim Arunee Dechaphunkul Jedzada Maneechavakajorn Neil Spector Thomas Yau Mehdi Afrit Slim Ben Ahmed Stephen R Johnston Neil Gibson Martina Uttenreuther-Fischer Javier Herrero Charles SwantonAbstract
Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer associated with HER2 amplification, with high risk of metastasis and an estimated median survival of 2.9 y. We performed an open-label, single-arm phase II clinical trial (ClinicalTrials.gov NCT01325428) to investigate the efficacy and safety of afatinib, an irreversible ErbB family inhibitor, alone and in combination with vinorelbine in patients with HER2-positive IBC. This trial included prospectively planned exome analysis before and after afatinib monotherapy.
Journal details
Journal PLOS Medicine
Volume 13
Issue number 12
Pages e1002136
Available online
Publication date
Full text links
Publisher website (DOI) 10.1371/journal.pmed.1002136
Figshare View on figshare
Europe PubMed Central 27923043
Pubmed 27923043